Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only postpartum depression pill approved in the United States, the companies said on ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the ...

Actress and talk show host Busy Philipps as well as sports reporter Jay Glazer have both headed up separate campaigns for Qelbree, a non-stimulant ADHD treatment manufactured by Supernus. This marks a ...

Supernus CEO Jack Khattar said the deal adds a “significant fourth growth product to our portfolio and further diversifies ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit ...

Supernus (NASDAQ:SUPN), the Rockville, Maryland headquartered developer of drugs to treat central nervous system ("CNS") conditions, will announce its Q1 2025 earnings next Tuesday, 6th May.